FDA Approves Two Immunotherapies for Advanced Melanoma
Metastatic melanoma patients have received very good news with the FDA’s approval of two important new immune-boosting therapies.
FDA Approves Second Targeted Combination Therapy for Advanced Melanoma
Published on November 18, 2015
On November 10, the US Food and Drug Administration (FDA) approved the combination targeted therapy vemurafenib-cobimetinib (Zelboraf-Cotellic) for about half of all …
New Genetic Study Strengthens Link Between UV Radiation and Melanoma
A new study appearing in the journal Nature greatly reinforces the findings of an earlier landmark genetic study linking damage from the sun’s ultraviolet rays (UVR) to melanoma, the …
New Study Shows Zelboraf Can Double Melanoma Patients’ Life Expectancy
A new study published in the February 22, 2012 issue of the New England Journal of Medicine shows that the drug ZelborafTM can reduce or eliminate tumors, delay disease progression, and extend life …
Nonmelanoma Skin Cancers Raise the Risk for Other Cancers
People who have had the nonmelanoma skin cancers (NMSCs) basal and squamous cell carcinoma (BCC and SCC) are approximately twice as likely as other people to develop non-skin cancers, according to a …
Melanoma Affects Women More Strongly than Men
IN THE HEADLINES...Melanoma appears to have a stronger overall impact on women than men, according to a new report.
In a study of 562 men and women published this month in the Archives of …